MetabolicHuman RCT
Tesamorelin in HIV: the trial that showed it trims deep belly fat, and what it cost
Six months of daily tesamorelin cut visceral fat by 15.2% while placebo users gained 5.0%. Nearly half of users developed antibodies to the drug.
Tesamorelin
A stabilised GHRH analogue approved in the US to reduce excess abdominal fat in adults with HIV, backed by two phase 3 trials of 806 people.
- Also known as
- Egrifta, Egrifta SV, Egrifta WR, TH9507
- Area
- Hormones
- Status
- FDA-approved (Egrifta) for HIV-associated abdominal fat; EU application withdrawn 2012
Articles on Tesamorelin
HormonesHuman RCT
Tesamorelin: the one GHRH drug with phase 3 evidence, and what it does and doesn’t show
In two phase 3 trials of 806 people with HIV, tesamorelin cut deep belly fat by about 15% more than placebo. The fat came back when it stopped, and nobody has run the trials people now cite it for.